Browse studies

Find your next paid study

1 recruiting study matching your filters

An Open Label, Dose Range, Proof-of-Concept Study to Assess the Safety and Efficacy of HM15421/GC1134A in Patients With Fabry Disease

This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.

Fabry Disesase

Estimated

~$10 – $8,750

GC Biopharma CorpNCT06858397